Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~* Patients with known classic CAH due to 21-hydroxylase deficiency as evidenced by hormonal and genetic testing~* Male or female patients 18 years or older~* Females must have a negative pregnancy test initially and at all visits. Sexually active females must be using a medically acceptable method of contraception.~* Patients with elevated adrenal androgens (defined as 17-OHP \>1200 ng/dL and androstenedione \>210 ng/dL)~* One or more co-morbidities:\<TAB\>~* Obesity \[body mass index (BMI) greater than 30.0 kg/m(2)\]~* Fatty liver disease; assessed by AST/ALT liver enzyme ratio (AST to ALT ratio \<1 (11)) liver ultrasound or MRI imaging (Steatosis score as previously described)~* Low insulin sensitivity; assessed by the Homeostasis Model Assessment Insulin Resistance (HOMA-IR) method \[HOMA-IR = insulin (micro U/ml) times glucose (mmol/L)/ 22.5\]. Elevated HOMA-IR index is defined as \>2.6 in adults17.~* Osteopenia \[bone mineral density by DEXA (at the spine, hip, or forearm) with T-score of -1 to -2.5) or osteoporosis (bone mineral density by DEXA (at the spine, hip, or forearm) with T-score of \<-2.5\] defined according to World Health Organization (WHO).~* Glucocorticoid-related gastrointestinal side effects (nausea, vomiting, dyspepsia, anorexia, gastritis, peptic ulcer disease and gastric bleeding)~EXCLUSION CRITERIA:~* Co-morbid conditions requiring daily administration of medications that induce hepatic enzymes or interfere with the metabolism of glucocorticoids~* Females who are pregnant or lactating~* Patients on inhaled or oral steroids given for reasons other than treatment of CAH~* Women who have taken estrogen-containing oral contraceptive pills within 6 weeks of recruitment~* Patients who required stress dose glucocorticoids for an illness within 4 weeks of recruitment~* Patients who changed their glucocorticoid agent within 3 months of recruitment~* Patients who underwent bilateral adrenalectomy~* Co-morbid conditions that could interfere with the ability to comply to the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Continuous Subcutaneous Hydrocortisone Infusion (Type: EXPERIMENTAL): Enrolled participants with congenital adrenal hyperplasia (CAH) received continuous subcutaneous hydrocortisone (Solucortef) infusion (CSHI) via insulin pump (Medtronic) (MMT-722Na) to achieve near-physiologic cortisol replacement therapy. Participants were their own controls; participant's baseline outcomes/lab values while on conventional glucocorticoid therapy were compared to outcomes/lab values after 6 months of treatment using CSHI via insulin pump.

Based on this trial design, predict the completion outcome and termination type (if applicable).